Nymox Pharmaceutical Corporation NYMXF
OTC PK
| 12/31/2024 | 09/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 164.00K | 142.00K | 2.83M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 788.00K | 653.00K | 4.85M | ||
| Operating Income | -788.00K | -653.00K | -4.85M | ||
| Income Before Tax | -857.00K | -716.00K | -5.31M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -857.00K | -716.00K | -5.31M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -857.00K | -716.00K | -5.31M | ||
| EBIT | -788.00K | -653.00K | -4.85M | ||
| EBITDA | -788.00K | -652.70K | -4.85M | ||
| EPS Basic | -0.01 | -0.01 | -0.06 | ||
| Normalized Basic EPS | -0.01 | 0.00 | -0.03 | ||
| EPS Diluted | -0.01 | -0.01 | -0.06 | ||
| Normalized Diluted EPS | -0.01 | 0.00 | -0.03 | ||
| Average Basic Shares Outstanding | 94.06M | 93.54M | 91.79M | ||
| Average Diluted Shares Outstanding | 94.06M | 93.54M | 91.79M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||